↓ Skip to main content

Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges

Overview of attention for article published in Stem Cell Research & Therapy, December 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users
facebook
1 Facebook page

Citations

dimensions_citation
151 Dimensions

Readers on

mendeley
148 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges
Published in
Stem Cell Research & Therapy, December 2017
DOI 10.1186/s13287-017-0727-7
Pubmed ID
Authors

Arash Aghajani Nargesi, Lilach O. Lerman, Alfonso Eirin

Abstract

Novel therapies are urgently needed to address the rising incidence and prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD). Mesenchymal stem/stromal cells (MSCs) have shown promising results in experimental AKI and CKD, and have been used in the clinic for more than a decade with an excellent safety profile. The regenerative effects of MSCs do not rely on their differentiation and ability to replace damaged tissues, but are primarily mediated by the paracrine release of factors, including extracellular vesicles (EVs), composed of microvesicles and exosomes. MSC-derived EVs contain genetic and protein material that upon transferring to recipient cells can activate several repair mechanisms to ameliorate renal injury. Recent studies have shown that MSC-derived EV therapy improved renal outcomes in several animal models of AKI and CKD, including ischemia-reperfusion injury, drug/toxin-induced nephropathy, renovascular disease, ureteral obstruction, and subtotal nephrectomy. However, data about the renoprotective effects of EV therapy in patients with renal failure are scarce. This review summarizes current knowledge of MSC-derived EV therapy in experimental AKI and CKD, and discusses the challenges that need to be addressed in order to consider MSC-derived EVs as a realistic clinical tool to treat patients with these conditions.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 148 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 148 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 22 15%
Student > Ph. D. Student 21 14%
Student > Master 18 12%
Researcher 14 9%
Other 12 8%
Other 23 16%
Unknown 38 26%
Readers by discipline Count As %
Medicine and Dentistry 35 24%
Biochemistry, Genetics and Molecular Biology 26 18%
Agricultural and Biological Sciences 16 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 3%
Nursing and Health Professions 4 3%
Other 18 12%
Unknown 44 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2019.
All research outputs
#14,369,287
of 23,009,818 outputs
Outputs from Stem Cell Research & Therapy
#1,108
of 2,429 outputs
Outputs of similar age
#237,330
of 439,388 outputs
Outputs of similar age from Stem Cell Research & Therapy
#30
of 58 outputs
Altmetric has tracked 23,009,818 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,429 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,388 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.